-
Published 4/3/2025
Jayasinghe T, Drainoni ML, Walley A, Grella C, Majeski A, Rolles A, Cogan A, Venkatesan G, Stein MD, Larochelle M, Samet JH, Kimmel SD. "Every Time I Go in There, It Gives Me Time to Reflect": A Qualitative Study of Patient Perspectives on Substance Use, Medications for Opioid Use Disorder, and Harm Reduction Following Hospitalization for Serious Injection-Related Infection. Open Forum Infect Dis. 2025 May; 12(5):ofaf201. PMID: 40352630.
-
Published 4/1/2025
Stopka TJ, Dalvi N, Young LD, Shrestha S, Valerio DD, Walley AY. Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing. JAMA Netw Open. 2025 Apr 01; 8(4):e253158. PMID: 40184073.
-
Published 3/19/2025
Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Mar 19. PMID: 40104887.
-
Published 2/5/2025
McCann NC, Yan S, McMahan VM, Pope E, Rolles A, Brennan S, Marti XL, Kosakowski S, Coffin PO, Walley AY. Test-Retest Reliability of a Timeline Follow-back Method to Assess Opioid Use and Treatment. J Addict Med. 2025 Feb 05. PMID: 39908533.
-
Published 1/23/2025
Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley AY, Komaromy M, Green TC. Developing a comprehensive inventory to define harm reduction housing. Harm Reduct J. 2025 Jan 23; 22(1):11. PMID: 39849487.